Abstract 324P
Background
HLX10, a fully humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor blocking PD-1, increased functional activities of human T-cells and showed in-vitro antitumour activity in xenograft models. The combined inhibition of PD-1 and VEGFR pathways may enhance a sustained suppression of cancer-related angiogenesis and tumour growth. Here, we present the phase 1 study data of HLX10 and the development of HLX10 as targeted combination immunotherapy.
Methods
We conducted an open-label, dose-finding with Bayesian optimal interval adaptive design study to evaluate safety, maximum tolerated dose, PK and clinical activity of HLX10 in patients with advanced or metastatic solid tumours refractory to standard therapy. Patients (pts) received biweekly i.v. infusions of HLX10 at doses of 0.3, 1, 3 and 10 mg/kg until disease progression, intolerable toxicities or withdrawal from the study. The dose-limiting toxicities were observed for 28 days after treatment. Clinical response was evaluated every 8 weeks for the first 24 weeks followed by every 12 weeks. Safety, PK and clinical response evaluations were performed throughout the study.
Results
As of 27-June-2019, 16 pts were dosed with HLX10 at various doses and maintained >90% PD1 receptor occupancy on the peripheral T-cells. Among 13 pts being evaluated for efficacy, 2 pts each at 0.3 and 3 mg/kg cohorts achieved stable disease; 1 pt at 3 mg/kg cohort achieved partial response with the longest follow-up time of 220 days. No infusionrelated reaction or additional safety signal was observed up to 10 mg/kg. The PK profiles demonstrated dose proportional manner as shown in the table.Table:
324P The PK parameters of 0.3 mg/kg and 3 mg/kg cohorts
Dose(mg/kg) | Cmax (μg/mL) | AUC0-t (h* μg/mL) | t1/2 (h) | |||
---|---|---|---|---|---|---|
- | C1D1 | C3D1 | C1D1 | C3D1 | C1D1 | C3D3 |
0.3 | 5.3 | 6.3 | 702.1 | 957.1 | 183.4 | 183.0 |
3 | 74.8 | 117.2 | 10823.6 | 27750.9 | 259.7 | 489.81 |
Conclusions
HLX10 is well tolerated, shows promising antitumour activities with durable objective responses in various cancers, and exhibits similar PK results to pembrolizumab and nivolumab. HLX10 is currently being tested in the first China combo-immunotherapy studies with HLX04 (a bevacizumab biosimilar) in advanced solid tumours with the longest follow-up time of > 200 days as of 20-June-2019 and in first-line treatment of metastatic NSCLC.
Clinical trial identification
HLX10-001(Registration Number: NCT0346875) monotherapy in advanced solid tumours; HLX10HLX04-001(Registration Number: NCT03757936) combo-immunotherapy in advanced solid tumours; HLX10-002-NSCLC301(Registration Number: NCT03952403) combo-immunotherapy in NSCLC.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc; Taiwan Henlix Biotech., Co.,LTD.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
T.Y. Chao: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Ho: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W.H. Cheng: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Chang: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. Y.Y. Hsieh: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W. Jiang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S. Liu: Full / Part-time employment: Shanghai Henlius Biotech,Inc. A. LUK: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S.F. Lin: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. T.C. Hsieh: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. E. Liu: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract